Cinaciguat is a potent guanylate cyclase stimulator utilized as an anti-anginal agent to support the treatment of chronic and acute decompensated heart failure. By enhancing nitric oxide levels, this therapeutic… Read more
Cinaciguat is a potent guanylate cyclase stimulator utilized as an anti-anginal agent to support the treatment of chronic and acute decompensated heart failure. By enhancing nitric oxide levels, this therapeutic agent promotes vasodilation and improves cardiac output for patients with reduced ejection fraction. Laboratories performing critical analysis on this compound require high-quality reference standards to ensure the accuracy of their results. This category provides access to Cinaciguat Hydrochloride, along with essential impurities, metabolites, and stable isotope-labelled compounds. These materials are fundamental for rigorous impurity profiling, the validation of analytical methods such as HPLC and LC-MS, and ongoing quality control protocols. Chemists and researchers rely on these verified compounds to detect degradation products, monitor metabolic pathways, and maintain compliance throughout the drug development and manufacturing lifecycle of this cardiovascular therapy.